Chugai Pharmaceutical Halts Development of R212 Lipase Inhibitor

Chugai Pharmaceutical announced on April 4 that it has decided to halt the development of R212, a drug candidate for the treatment of obesity, in Japan. The company has come to the decision because it faces obstacles such as further expenditure on additional dose-response studies and clinical trials. Having made the decision, the company will concentrate its R&D resources in other targets. Further, Chugai and Roche will jointly look for licensing partners for R212 in Japan.

Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=22476&nfid=rssfeeds)